Clinical Trials Using Trabectedin

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Trabectedin. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Avelumab and Trabectedin in Treating Patients with Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

    This phase I / II studies the side effects of avelumab and trabectedin and how well they work in treating patients with leiomyosarcoma or liposarcoma that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as avelumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving avelumab and trabectedin may work better in treating patients with liposarcoma or leiomyosarcoma.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma

    This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Immune Changes following Trabectedin in Patients with Metastatic or Unresectable Sarcoma

    This research trial studies the immune changes following trabectedin in patients with sarcoma that has spread to other places in the body or cannot be removed by surgery. Analyzing tumor tissue may help to understand the changes in immune cells in or around the tumor or if there is an increase in immune cells in the tumor after receiving trabectedin.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington